The following key staff are responsible for delivering the Lamellar Business Plan in terms of Preclinical and Clinical Development, Quality and Regualory Affairs.

Dr Alec McLean BSc CEO

Alec bw 3Alec has more than 30 years’ experience in respiratory research covering 9 years basic clinical pulmonary research at Edinburgh University Medical School, 9 years’ drug development with Astra Pharmaceuticals and 14 years in the CRO industry at Quintiles. This included extensive Phase 1-4 global clinical drug development, as Senior Director for global Allergy and Respiratory project management as well as commercial input, product development strategy and product and company due diligence.

At any one point in time the value of the studies he had P&L responsibility for exceeded $300m, with yearly sales typically around $100m. Alec delivered pivotal studies for a range of pharma companies from blue chip e.g. Roche, AZ, Merck, Novartis and J&J to emerging biotechs e.g. Vertex, Stallergenes and Inspire.


Steven Porteous BSc Director of Clinical and Regulatory

Steven bw 3Steven brings his experience as a Global Associate Director of Respiratory Project Management at Quintiles to Lamellar to coordinate Lamellar’s Clinical and Regulatory activities. Steven has developed close working relationships with The Beatson West of Scotland Cancer Centre; Glasgow Caledonian University, Vision Sciences; and the West of Scotland CF Centre to ensure expert input to Lamellar’s clinical development programs.

 


Dr Lynsey Howard BSc Lead Scientist Pre-Clinical Research and Development

Lynsey bw 1Lynsey coordinates Lamellar’s internal and external pre-clinical research activities through a Lamellar Body research forum whose aim is to advance the understanding of this hitherto neglected but vitally important part of the body’s protective systems. The MSAB is working closely with Lynsey.

 

 


Karen Hutcheson Head of Quality Management and Business Administration

Karen bw 2Karen has overseen Lamellar’s successful ISO 13485:2003 and ISO 9001:2008, which have been in place since 2013 and been maintained through successive audits. Karen is also overseeing Lamellar’s CE Device accreditation program for the Dry Mouth and Dry Eye applications.